HIT Consultant March 21, 2024
What You Should Know:
– Cybin Inc. (NYSE American: CYBN), a company developing next-generation psychedelic therapies for mental health, has secured $150M in a private placement of common shares led by Deep Track Capital and included participation from other institutional investors. The price per share was set at $0.43, representing a 17% premium over the 10-day volume-weighted average trading price.
– The funding will fuel the development of CYB003, a potential first-in-class psychedelic treatment for major depressive disorder (MDD).
Developing Differentiated, Next-Gen Psychedelic Therapeutics
Founded in 2019, Cybin is a clinical-stage biopharmaceutical company dedicated to developing safe and effective psychedelic treatments for mental health conditions. Their approach leverages a...
Today's Sponsors
Today's Sponsor